相关实验视频

Updated: Sep 19, 2025

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

突变的KRAS针对为癌症治疗而设计的CAR-T细胞

Alexander Benton¹, Jiageng Liu², Mathilde A Poussin³

¹Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Pharmacology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

|June 6, 2025

概括

这项研究开发了一种新的仿真抗原受体 (CAR) -T细胞疗法,针对固体瘤中的KRAS G12V突变. 设计的mKRAS NeoCAR在临床前模型中显示出有效性,提高了安全性和有效性.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因工程是一种基因工程.

背景情况:

化学抗原受体 (CAR) -T细胞疗法在血液癌症中表现有前途,但由于疗效和毒性,在固体瘤中面临挑战.
开发针对异质和免疫抑制固体瘤的向免疫疗法需要新的策略.
瘤性KRAS突变,如KRAS G12V,是许多固体瘤的常见驱动因素.

研究的目的:

开发和评估一种新的CAR-T细胞疗法,针对实体瘤中的瘤性KRAS G12V突变.
设计 CAR-T 细胞以提高疗效和安全性,用于治疗转移性肺癌,胰腺癌和细胞癌.
建立一个模块化平台,用于创建针对癌症的先进细胞免疫疗法.

主要方法:

选向KRAS G12V突变的结合剂,由-MHC复合体呈现.
开发KRAS特异性CAR-T细胞 (mKRAS NeoCARs),其中包含已识别的结合剂.
通过诱导IL-12分泌和T细胞受体缺失在异种移植模型中增强体内疗效和安全性.

主要成果:

在转移性肺癌,胰腺癌和脏细胞癌的异种移植模型中证明了mKRAS NeoCARs的有效性.
成功提高了mKRAS NeoCARs的体内疗效和安全性.
验证了一个模块化平台,用于开发向癌症免疫疗法.

结论:

开发的mKRAS NeoCARs代表了对KRAS G12V突变固体瘤的有前途的细胞免疫疗法.
新抗原向和基因工程的结合提高了CAR-T细胞的治疗指数.
该平台提供了一种通用方法,用于扩大细胞免疫疗法在瘤学中的应用.

关键词:

汽车车上的车辆.克里斯普尔是什么意思?克里斯普尔是什么意思?在IL-12中,IL-12是最重要的.克拉斯 (Kras) 是一个国家.一个T细胞细胞.装甲汽车 (CAR) 装甲车细胞免疫疗法细胞免疫疗法新抗原是一种新抗原.这是一种类.固体瘤是一种固体瘤.治疗指数治疗指数

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...